Exploring Practical CAR T Cell Use in Multiple Myeloma Care

Experts discuss the roles that telemedicine and outpatient programs can play in increasing access to novel cellular therapies among those with multiple myeloma.

Toxicity management for patients who receive CAR T-cell therapy for multiple myeloma is improving, according to Marco Davila, MD, PhD.

Academic clinicians have an incumbent role to improve access to novel cellular therapies, according to Marco Davila, MD, PhD.

Joshua Richter, MD, and Marco Davila, MD, PhD, focused on real-world CAR T-cell therapy outcomes in multiple myeloma.

Joshua Richter, MD, and Marco Davila, MD, PhD, discussed what are some optimal candidates for CAR T-cell therapy in multiple myeloma.

Joshua Richter, MD, and Marco Davila, MD, PhD, weighed in on sequencing CAR T-cell therapy and bispecifics in multiple myeloma.

Joshua Richter, MD, and Marco Davila, MD, PhD, weighed in on the optimal timing of CAR T-cell therapy for multiple myeloma.

Stay tuned for an in-depth discussion on navigating operational workflows and mitigating barriers to access for CAR T-cell therapy in multiple myeloma.

Two hematologic oncology experts discuss operational and referral workflows, as well as barriers to access for CAR T-cell therapy in multiple myeloma.